Pharmacologic principles Flashcards

1
Q

Are lipophilic or hydrophilic compounds more likely to penetrate the blood ocular/retinal barriers

A

lipophilic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Define bioavailability

A

rate at which an active drug reaches the site of action and the extent to which it is available to the target tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Define biologic agent

A

product made from living organisms or containing components of living organisms and used in the prevention, diagnosis, or treatment of disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Define emulsion

A

mixture of 2 immiscible components

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Define pharmacodynamics

A

study of the biochemical and physiological effects of drugs/
agents on a biological system, including the mechanisms of their actions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Define Pharmacokinetics

A

study of the absorption, distribution, metabolism, and excretion of drugs/agents in a biological system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Define pharmacology

A

study of drug action, the interactions of living organisms with therapeutic substances through biochemical processes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Define pharmacotherapeutics

A

study of how to achieve the desired effects, or prevent/ minimize the adverse effects or toxicity, of a drug or agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Define suspension

A

mixture of a substance with poor solubility and a dispersion medium in which the substance is evenly distributed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Do topically applied medication increase or decrease systemic bioavailability

A

avoids the first-pass metabolism of the liver and increases systemic bioavailability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Examples of preservatives used in topical treatment

A

benzalkonium chloride and benzododecinium bromide; mercurial agents such as thimerosal, chlorobutanol, and parahydroxybenzoates; and aromatic alcohols

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How are topical drops absorbed into the eye

A

The drug gradient, from the concentrated tear reservoir to the relatively barren corneal and conjunctival epithelia, forces a passive route of absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How much of a topically administered medication is retained

A

20% at most due to rapid turnover of fluid in tear lake. For slowly absorbed drugs at most only 50% absorbed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the residence time of a medication

A

The amount of time that a drug remains in the tear reservoir and tear film. This time is affected not only by drug formulation but also by the timing of subsequent medication, tear production, and drainage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Examples of suspension medication

A

Prednisolone acetate and brinzolamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Examples of emulsion medications

A

emulsions have the advantages of increased contact time (because of the adsorption of nanodroplets on the corneal surface) and greater bioavailability. Difluprednate and cyclosporine are examples of a topical emulsion.

17
Q

What is the effect of high viscosity medication

A

addition of high-viscosity substances such as methylcellulose and polyvinyl alcohol (PVA) to a drug increases drug retention in the inferior cul-de-sac, aiding drug penetration. An example is timolol maleate

18
Q

What is the optimal viscosity for drug delivery

A

the optimal viscosity is 12–15 cP

19
Q

What is important in corneal permeability

A

Lipid solubility is more important than water solubility

20
Q

How to increase partition coefficients and drug penetration

A

by raising the pH of the water phase, thereby increasing the proportion of drug molecules in the more lipid-soluble, uncharged form

21
Q

Effect of surfactants on ocular medication delivery

A

preservatives used in topical drops to prevent bacterial contamination are surfactants (also called surface-active agents) that alter cell membranes in the cornea as well as in bacteria, reducing the barrier effect of the corneal epithelium and increasing drug penetration

22
Q

When does reflex tearing occur

A

Ocular irritation and secondary tearing wash out the drug reservoir in the tear lake and reduce the contact time of the drug with the cornea. Reflex tearing occurs when topical medications are not isotonic and when they have a nonphysiologic pH or contain irritants

23
Q

How can binding of medications lead to toxicity

A

Tear and ocular surface proteins, as well as ocular melanin, may bind topical or systemic medication, making the drug unavailable or creating a slow-release reservoir. An example of this effect is the retinal toxicity that progresses even after discontinuation of the aminoquinoline antimalarial drugs chloroquine and hydroxychloroquine.

24
Q

Condition which can occur if preservative containing antibiotics are used intraocularly

A

Toxic anterior segment syndrome (TASS)

25
Q

Does chloramphenicol or penicillin have greater lipid solubility

A

rugs with higher lipid solubility more readily penetrate the blood–ocular barrier. Thus, chloramphenicol, which is highly lipid-soluble, penetrates 20 times better than does penicillin, which has poor lipid solubility

26
Q

What is the relationship between plasma protein bound medications and blood-ocular barrier permeability

A

Only the unbound form can cross the blood–ocular barrier. Sulfonamides are lipid-soluble but penetrate poorly because, at therapeutic levels, more than 90% of the medication is bound to plasma proteins. Similarly, compared with methicillin, oxacillin has reduced penetration because of its increased binding of plasma proteins

27
Q

Why is the intraocular penetration of an intravenous medication better in the inflamed eye

A

because of the disruption of the blood–aqueous and blood–retina barriers that occurs with inflammation

28
Q

What are ophthalmic prodrugs

A

They are therapeutically inactive derivatives of drug molecules that are designed to be activated by enzymatic systems within the eye in order to improve ocular penetration. Prostaglandin analogues are successful examples of this drug delivery strategy. Latanoprost, travoprost, and tafluprost are prostaglandin analogues that interact with the prostaglandin FP receptor. They require hydrolyzation prior to becoming active compounds in the eye.

29
Q

How do soluble drug inserts work

A

Soluble inserts release the drug via interaction between the polymeric matrix of the device and the tear film. Removal of these inserts is unnecessary

30
Q

How do insoluble drug inserts work

A

Insoluble inserts may achieve a more constant rate of drug release than soluble inserts, but removal of the device is required

31
Q

Examples of intravitreal implants

A

The first-available sustained-release implant was the ganciclovir intravitreal implant for treatment of cytomegalovirus (CMV) retinitis. After surgical implantation, the device delivered a steady source of ganciclovir for 5–8 months. Current intraocular sustained-release products include 2 fluocinolone acetonide intravitreal implants (0.59 mg and 0.19 mg) and a dexamethasone intravitreal implant.

32
Q

Use of 0.59mg 2 fluocinolone implant

A

a nonbiodegradable intraocular polymer implant requiring surgical placement in the pars plana region for the treatment of chronic noninfectious posterior uveitis over approximately 30 months

33
Q

Use of 0.19mg fluocinolone implant

A

treatment of diabetic macular edema in patients who are not steroid responders over 36 months

34
Q

Use of 0.7-mg dexamethasone implant

A

The poly- mer degrades to lactic acid and glycolic acid, and dexamethasone is slowly released within the vitreous cavity. The implant is indicated for the treatment of macular edema secondary to retinal vein occlusion, noninfectious posterior uveitis, and diabetic macular edema

35
Q

What is an agonist

A

If the drug–receptor interaction stimulates the receptor’s natural function, the drug is termed an agonist

36
Q

What is an antagonist

A

Stimulation of an opposing effect characterizes an antagonist. Corresponding effectors of enzymes are termed activators and inhibitors